Lachey Jennifer 4
4 · Keros Therapeutics, Inc. · Filed Apr 13, 2022
Insider Transaction Report
Form 4
Lachey Jennifer
Chief Scientific Officer
Transactions
- Sale
Common Stock
2022-04-11$62.32/sh−1,009$62,881→ 88,574 total - Sale
Common Stock
2022-04-11$64.15/sh−559$35,860→ 85,700 total - Exercise/Conversion
Common Stock
2022-04-11$0.30/sh+5,300$1,590→ 91,000 total - Sale
Common Stock
2022-04-11$61.37/sh−1,417$86,961→ 89,583 total - Sale
Common Stock
2022-04-11$63.50/sh−2,315$147,003→ 86,259 total - Exercise/Conversion
Employee Stock Option (right to buy)
2022-04-11−5,300→ 71,405 totalExercise: $0.30Exp: 2028-03-25→ Common Stock (5,300 underlying)
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.97 to $61.935 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5).
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.975 to $62.97 inclusive.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.975 to $63.865 inclusive.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.00 to $64.49 inclusive.
- [F6]Immediately exercisable.